Skip to main content
SpringerLink
Log in

Early FDG-PET response–adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Prognostic index for Hodgkin's disease according to Hasenclever. European Society of Medical Oncology. http://www.esmo.org/education/practice-tools/web-based-practice-tools/hasenclever-index-for-hodgkins-disease.html. Accessed September 13, 2009.

  2. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339:1506–14.

    Article  CAS  PubMed  Google Scholar 

  3. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22–8.

    Article  PubMed  Google Scholar 

  4. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.

    Article  CAS  PubMed  Google Scholar 

  5. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.

    Article  CAS  PubMed  Google Scholar 

  6. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.

    Article  CAS  PubMed  Google Scholar 

  7. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  CAS  PubMed  Google Scholar 

  8. Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma. 2007;48:1548–55.

    Article  CAS  PubMed  Google Scholar 

  9. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–95.

    Article  CAS  PubMed  Google Scholar 

  10. HD16 for early stage Hodgkin lymphoma. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00736320. Accessed September 13, 2009.

  11. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(Suppl 1):21S–30S.

    Article  CAS  PubMed  Google Scholar 

  12. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00795613. Accessed September 13, 2009.

  13. Tailoring treatment for B cell non-Hodgkin's lymphoma based on PET scan results mid treatment. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00324467. Accessed September 13, 2009.

  14. Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas (PETAL). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00554164. Accessed September 13, 2009.

Download references

Author information

Authors and Affiliations

  1. Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Parel, Bombay, 400012, India

    Sandip Basu

Authors
  1. Sandip Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandip Basu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basu, S. Early FDG-PET response–adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?. Eur J Nucl Med Mol Imaging 36, 2089–2090 (2009). https://doi.org/10.1007/s00259-009-1296-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1296-5

Keywords

Search

Navigation